--- title: "Dermata Therapeutics (DRMA) news: delisting and offering" url: "https://aibio.space/companies/dermata-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DRMA delisting, offering and Nasdaq notice news: Dermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice." --- DRMA Dermata Therapeutics, Inc. NASDAQ · United States # Dermata Therapeutics (DRMA) news DRMA delisting, offering and Nasdaq notice news Company Updates · 2026-10-29 ## [Dermata enrolls first participant in Tome Clearing Treatment trial](https://aibio.space/news/dermata-enrolls-first-participant-tome-clearing-treatment-trial/) Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch its second commercial product in the first half of 2027. ## Latest Dermata Therapeutics news 1. 2026-08-17 Financings [Dermata agrees to $3.4 million private placement with warrants](https://aibio.space/news/dermata-agrees-3-4-million-private-placement-warrants/) Dermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses. 2. 2026-08-11 Company Updates [Dermata reports second-quarter 2026 results and $4.4 million in cash](https://aibio.space/news/dermata-reports-second-quarter-2026-results-4-4-million-cash/) Dermata Therapeutics reported $4.4 million in cash and cash equivalents at June 30, 2026, and said it expects to launch Tome Foundational Treatment on August 25, 2026. Cash is expected to fund operations into the fourth quarter of 2026. 3. 2026-08-05 Company Updates [Dermata sets August 25, 2026 sale date for Tome Foundational Treatment](https://aibio.space/news/dermata-sets-august-25-2026-sale-date-tome-foundational-treatment/) Dermata Therapeutics expects its first commercial product, Tome Foundational Treatment, to be available for sale starting August 25, 2026. The set of four once-weekly treatments sells for $178, about $45 per treatment. 4. 2026-05-27 Listings [Dermata shareholders approve warrant repricing and larger equity plan](https://aibio.space/news/dermata-shareholders-approve-warrant-repricing-larger-equity-plan/) At its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected. 5. 2026-05-13 Financings [Dermata reports first-quarter 2026 results and $2.0 million in ATM proceeds](https://aibio.space/news/dermata-reports-first-quarter-2026-results-2-0-million-atm-proceeds/) Dermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027. 6. 2025-08-25 Listings [Dermata Therapeutics regains Nasdaq compliance after hearing panel exception](https://aibio.space/news/dermata-therapeutics-regains-nasdaq-compliance-after-hearing-panel/) Nasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure. 7. 2025-05-16 Listings [Dermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice](https://aibio.space/news/dermata-regains-nasdaq-stockholders-equity-compliance-but-gets-bid/) Dermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one. 8. 2025-03-28 Financings [Dermata Therapeutics expects $6.2 million as holders exercise warrants at $1.284](https://aibio.space/news/dermata-therapeutics-expects-6-2-million-holders-exercise-warrants-1/) Dermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares. 9. 2025-03-25 Listings [Dermata Therapeutics gets Nasdaq stockholders' equity deficiency notice, has until May 9, 2025](https://aibio.space/news/dermata-therapeutics-gets-nasdaq-stockholders-equity-deficiency-notice/) Dermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025. ## Dermata Therapeutics at a glance - **Ticker**: DRMA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $4.4 million ### Related companies - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [Citius Pharmaceuticals](https://aibio.space/companies/citius-pharmaceuticals/) NASDAQ: CTXR - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Impact BioMedical](https://aibio.space/companies/impact-biomedical/) AMEX: IBO - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER ### Also on NASDAQ - [Tenon Medical](https://aibio.space/companies/tenon-medical/) TNON - [Cardio Diagnostics Holdings](https://aibio.space/companies/cardio-diagnostics/) CDIO - [OPKO HEALTH, INC.](https://aibio.space/companies/opko-health/) OPK - [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) JANX - [QTREX Quantum](https://aibio.space/companies/qtrex-quantum/) QTEX - [Edgewise Therapeutics](https://aibio.space/companies/edgewise-therapeutics/) EWTX ## What Dermata Therapeutics does Dermata Therapeutics, Inc. describes itself as a scientific leader in skincare, dedicated to developing and commercializing products for common and underserved skin conditions. It was founded to develop prescription products. Its lead asset, XYNGARI (DMT310), was studied for moderate-to-severe acne, and in March 2025 the company reported statistically significant results from its Phase 3 STAR-1 trial across all three co-primary endpoints at weeks 4, 8 and 12 compared with placebo. In September 2025 management, with its board, chose a strategic shift to developing and distributing direct-to-consumer and business-to-business skincare products backed by science. Its hero ingredient is Spongilla lacustris, a freshwater sponge processed into a powder used in its Bioneedle. The company plans to launch its first cosmetic product in the middle of 2026, with a first over-the-counter acne product to follow shortly after. The planned OTC acne system pairs a weekly Bioneedle treatment with a daily salicylic acid wipe. The company also sees a market for its technology in intradermal delivery of botulinum toxin for aesthetic conditions. The text notes that there are over 50 million acne patients in the U.S. | Product or program | What it is | Stage | |---|---|---| | Bioneedle skin renewal treatment | Once-weekly skin renewal kit using 100% Spongilla lacustris powder | Cosmetic product launch planned for the middle of 2026 | | OTC topical acne system | Weekly Bioneedle treatment used with a daily salicylic acid wipe for acne | OTC product to follow the cosmetic launch | | XYNGARI (DMT310) | Former prescription candidate for moderate-to-severe acne | Phase 3 results statistically significant (March 2025); prescription development deprioritized | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/form10-k.htm). ## Dermata Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | [$8.2 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | | Net income (loss) | [-$7.6 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | [-$12.3 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | | Cash from operations | [-$7.8 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | | Cash and equivalents | [$7.5 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226037127/) | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1853816/000149315226012992/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dermata Therapeutics Was Dermata Therapeutics delisted? Our latest story on this, dated May 16, 2025: "Dermata regains Nasdaq stockholders' equity compliance but gets bid price delisting notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dermata-regains-nasdaq-stockholders-equity-compliance-but-gets-bid/). Has Dermata Therapeutics raised money recently? Our latest story on this, dated Aug 17, 2026: "Dermata agrees to $3.4 million private placement with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dermata-agrees-3-4-million-private-placement-warrants/). Has Dermata Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Mar 25, 2025: "Dermata Therapeutics gets Nasdaq stockholders' equity deficiency notice, has until May 9, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dermata-therapeutics-gets-nasdaq-stockholders-equity-deficiency-notice/). What is the ticker symbol of Dermata Therapeutics? Dermata Therapeutics, Inc. trades under the ticker DRMA on NASDAQ. Where is Dermata Therapeutics listed? Dermata Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Dermata Therapeutics? The SEC Central Index Key (CIK) for Dermata Therapeutics, Inc. is 1853816. Its filings are on SEC EDGAR. How many shares does Dermata Therapeutics have outstanding? 4,022,143 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Dermata Therapeutics listed under? Our directory records Dermata Therapeutics, Inc. under United States. What does Dermata Therapeutics do? Our directory classifies Dermata Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Dermata Therapeutics? The ISIN recorded for Dermata Therapeutics, Inc. is US2498455045. Does aibio.space cover Dermata Therapeutics? aibio.space lists Dermata Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dermata Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Dermata Therapeutics develop? Dermata Therapeutics, Inc. describes itself as a scientific leader in skincare, dedicated to developing and commercializing products for common and underserved skin conditions. It was founded to develop prescription products. What is Bioneedle skin renewal treatment from Dermata Therapeutics? Bioneedle skin renewal treatment: Once-weekly skin renewal kit using 100% Spongilla lacustris powder Stage: Cosmetic product launch planned for the middle of 2026. What is OTC topical acne system from Dermata Therapeutics? OTC topical acne system: Weekly Bioneedle treatment used with a daily salicylic acid wipe for acne Stage: OTC product to follow the cosmetic launch. ## Investor discussion: Dermata Therapeutics Members talk about Dermata Therapeutics (DRMA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dermata Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000149315226038647/ex99-1.htm) 2. 2026-02-03 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000149315226004905/form8-k.htm) 3. 2025-12-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000149315225029364/ex99-1.htm) 4. 2025-11-18 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/form8-k.htm) 5. 2025-08-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225025405/form8-k.htm) 6. 2025-07-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225021501/form8-k.htm) 7. 2025-07-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225019760/form8-k.htm) 8. 2025-07-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/form8-k.htm) 9. 2025-06-05 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225013823/form8-k.htm) 10. 2025-06-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225013237/formdef14a.htm) 11. 2025-05-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225012257/pre14a.htm) 12. 2025-05-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000164117225011286/form8-k.htm) 13. 2025-03-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000165495425003552/drma_ex991.htm) 14. 2025-03-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1853816/000165495425003305/drma_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DRMA on TradingView](https://www.tradingview.com/symbols/NASDAQ-DRMA/). ## SEC filings and registration - **SEC name**: Dermata Therapeutics, Inc. - **CIK**: 1853816 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DRMA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130 - **Phone**: (858)-223-0882 - **Shares outstanding**: 4,022,143 as of 2026-08-10 (10-Q filed 2026-08-11) - **Former names**: Dermata Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1853816/000149315226046518/forms-3.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1853816/000149315226038647/form8-k.htm) filed 2026-08-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1853816/000149315226037127/form10-q.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/form8-k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1853816/000149315226036109/form8-k.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1853816/000149315226025441/form8-k.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1853816/000149315226022719/form10-q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/form8-k.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001853816), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dermata Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DRMA, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dermata Therapeutics, Inc. - **Ticker**: DRMA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US2498455045 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DRMA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dermata-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dermata Therapeutics (DRMA) news: delisting and offering", 2026-10-31, https://aibio.space/companies/dermata-therapeutics/